Olfaction in Parkin single and compound heterozygotes in a cohort of young onset Parkinson's disease patients by Malek, N. et al.
This is an Open Access document downloaded from ORCA, Cardiff University's institutional
repository: http://orca.cf.ac.uk/103677/
This is the author’s version of a work that was submitted to / accepted for publication.
Citation for final published version:
Malek, N., Swallow, D. M. A., Grosset, K. A., Lawton, M. A., Smith, C. R., Bajaj, N. P., Barker, R.
A., Ben-Shlomo, Y., Bresner, Catherine, Burn, D. J., Foltynie, T., Morris, H. R., Williams, Nigel,
Wood, N. W. and Grosset, D. G. 2016. Olfaction in Parkin single and compound heterozygotes in a
cohort of young onset Parkinson's disease patients. Acta Neurologica Scandinavica 134 (4) , pp.
271-276. 10.1111/ane.12538 file 
Publishers page: http://dx.doi.org/10.1111/ane.12538 <http://dx.doi.org/10.1111/ane.12538>
Please note: 
Changes made as a result of publishing processes such as copy-editing, formatting and page
numbers may not be reflected in this version. For the definitive version of this publication, please
refer to the published source. You are advised to consult the publisher’s version if you wish to cite
this paper.
This version is being made available in accordance with publisher policies. See 
http://orca.cf.ac.uk/policies.html for usage policies. Copyright and moral rights for publications
made available in ORCA are retained by the copyright holders.
Olfaction in Parkin single and compound heterozygotes in a cohort 
of young onset Parkinson’s disease patients 
N. Malek1, D. M. A. Swallow1, K. A. Grosset1, M. A. Lawton2, C. R. Smith1, N. P. Bajaj3, R. A. 
Barker4, Y. Ben-Shlomo2, C. Bresner5, D. J. Burn6, T. Foltynie7, H. R. Morris8, N. 
Williams5,N. W.Wood9, D. G. Grosset1, on behalf of PRoBaND Investigators. 
1 Institute of Neurological Sciences, Queen Elizabeth University Hospital, Glasgow, UK;  
2 School of Social & Community Medicine, University of Bristol, UK;  
3 QueeŶ͛s MediĐal CeŶtƌe, NottiŶghaŵ, UK;  
4 Clinical Neurosciences, John van Geest Centre for Brain Repair, Cambridge, UK;  
5 Institute of Psychological Medicine and Clinical Neurosciences, Cardiff University, UK;  
6 Institute of Neuroscience, University of Newcastle, Newcastle upon Tyne, UK;  
7 Sobell Department of Motor Neuroscience, UCL Institute of Neurology, London, UK;  
8 Department of Clinical Neurosciences, University College London, UK;  
9 Department of Molecular Neuroscience, University College London, UK 
 
N. Malek, Institute of Neurological Sciences, Queen Elizabeth University Hospital, Glasgow 
G51 4TF, UK Tel.: 0141 201 2486 Fax: 0141 201 2510 e-mail:nmalek@nhs.net 
 
Background – PaƌkiŶ ƌelated PaƌkiŶsoŶ͛s disease (PD) is differentiated from idiopathic PD by 
aďseŶt oƌ spaƌse LeǁǇ ďodies, aŶd pƌeseƌǀed olfaĐtioŶ. The sigŶiﬁĐaŶĐe of siŶgle PaƌkiŶ 
mutations in the pathogenesis of PD is debated. Objectives – To assess olfaction results 
according to Parkin mutation status. To compare the prevalence of Parkin single 
heterozygous mutations in patients diagnosed with PD to the rate in healthy controls in 
order to establish whether these single mutations could be a risk factor for developing PD. 
Methods – Parkin gene mutation testing was performed in young onset PD (diagnosed <50 
years old) to identify three groups: Parkin homozygous or compound heterozygote mutation 
carriers, Parkin single heterozygote mutation carriers, and non-carriers of Parkin mutations. 
Olfaction was tested using the 40-item British version of the University of Pennsylvania 
sŵell ideŶtiﬁĐatioŶ test ;UPSITͿ. ‘esults – Of 344 young onset PD cases tested, 8 (2.3%) 
were Parkin compound heterozygotes and 13 (3.8%) were Parkin single heterozygotes. 
Olfaction results were available in 282 cases (eight compound heterozygotes, nine single 
heterozygotes, and 265 non-carriers). In Parkin compound heterozygotes, the median UPSIT 
score was 33, interquartile range (IQR) 28.5–ϯϲ.ϱ, ǁhiĐh ǁas sigŶiﬁĐaŶtlǇ ďetteƌ than in 
single Parkin heterozygotes (median 19, IQR 18–28) and non-carriers (median score 22, IQR 
16–28) (ANOVA P < 0.001). These differences persisted after adjusting for age, disease 
duƌatioŶ, geŶdeƌ, aŶd sŵokiŶg ;P < Ϭ.ϬϬϭͿ. Theƌe ǁas Ŷo sigŶiﬁĐaŶt difference in UPSIT 
scores between single heterozygotes and non-carriers 
(P = 0.90). Conclusions – Patients with Parkin compound heterozygous mutations have 
relatively preserved olfaction compared to Parkin single heterozygotes and non-carriers. The 
prevalence of Parkin single heterozygosity is similar to the 3.7% rate reported in healthy 
controls. 
 
Introduction 
Olfactory dysfunction is an important early pre-ŵotoƌ sigŶ of PaƌkiŶsoŶ͛s disease ;PDͿ aŶd is 
pre-sent in nearly 90% of cases (1). Preserved or mildly impaired olfactory function in a 
parkinsonian patient is more likely to be related to vascular parkinsonism or atypical 
parkinsonism such as multiple system atrophy (MSA), progressive supranuclear palsy (PSP), 
or corticobasal degeneration (CBD), whereas markedly reduced olfaction is more suggestive 
of idiopathic PD (2, 3). 
Bi-allelic Parkin mutations causing parkinsonism have been postulated as a different 
diseaseentity compared to idiopathic PD, based on young age at onset (invariably before 
age 50 years), relatively preserved olfactory function (4), and absent or sparse Lewy bodies 
(5). 
Impaired olfaction may predate a clinical diagnosis of PD by at least 4 years, based on 
population data from older males, and is proposed therefore as a useful screening tool for 
͚at ƌisk͛ suďjeĐts ;e.g., those ǁith a positiǀe faŵilǇ histoƌǇͿ to deteĐt those at a higher risk for 
later development of PD (6). Parkin mutations are inherited in an autosomal recessive 
manner; Parkin mutations can be single heterozygous (i.e. a mutation in 1 allele), 
homozygous (i.e. the same mutation in 2 alleles), or compound heterozygous (i.e. different 
mutations in 2 alleles). Young age at onset, race/ethnicity, and family history of PD are 
predictors of carrying Parkin mutations (7). 
Earlier studies indicated that olfaction is not impaired among patients with PD who have 
Par-kin compound heterozygote mutations (or homozygote status). These patients had 
sigŶiﬁĐaŶtlǇ higheƌ UŶiǀeƌsitǇ of PeŶŶsǇlǀaŶia sŵell ideŶtiﬁĐatioŶ test ;UPSITͿ sĐoƌes 
compared to single heterozygotes or non-carriers, and the differences persisted after 
adjustment for other factoƌs that iŶﬂueŶĐe olfaĐtoƌǇ sĐoƌes, ŶaŵelǇ age, geŶdeƌ, aŶd 
disease duration (8). This then raises the question whether single Parkin mutations are 
incidental to the diagnosis of PD, rather than playing a role in the development of the PD 
phenotype when present (9). The background prevalence of Parkin single heterozygosity is 
ϯ.ϳ% iŶ healthǇ suďjeĐts, ǁhiĐh is a useful ƌefeƌeŶĐe ﬁguƌe foƌ Đoŵpaƌison to a PD cohort 
(10). 
We systematically evaluated olfactory function and Parkin mutation status in a cohort of 
ǇouŶg oŶset PD Đases to deﬁŶe the pƌeǀaleŶĐe aŶd seǀeƌitǇ of olfaĐtory dysfunction in 
Parkin mutatioŶ Đaƌƌieƌs ǁith PD Đlassiﬁed ďǇ geŶotǇpe ;single heterozygous, compound 
heterozygous or homozygous) and non-carriers. 
 
Methods 
 
Subjects 
PaƌtiĐipaŶts iŶ the pƌiŵaƌǇ aŶalǇsis ǁeƌe eŶƌolled iŶ the TƌaĐkiŶg PaƌkiŶsoŶ͛s studǇ, a 
multicentre study in the United Kingdom (UK) which includes two PD patient cohorts: young 
onset cases (diagnosed at age <50 years), and recent onset cases (diagnosed within the last 
3 years). The study protocol includes olfactory assessment and detailed motor, non-motor, 
and quality-of-life scoring. The diagnosis of PD was made according to the Queen Square 
Brain Bank criteria (11.) Cases who were diagnosed with vascular, drug-induced, and 
atypical parkinsonism (MSA, CBD, PSP) were excluded (12). Parkin mutation status was 
determined, for practical reasons, in patients diagnosed under 50 years of age in the young 
onset cohort, and under 45 years of age in the recent onset cohort, making a total of 344 
Đases. Cases ǁeƌe Đlassiﬁed iŶto thƌee gƌoups: ďi-allelic Parkin mutation carriers, single 
Parkin mutation carriers, and Parkin non-carriers. The study procedures were approved by 
the West of Scotland Research Ethics committee and performed according to the 
Declaration of Helsinki. All subjects provided written informed consent. 
 
Olfaction 
Olfaction testing was performed using the British version of the 40-item UPSIT test (13). 
These smell tests were self-administered in outpatient clinics; patients were given verbal 
guidance which followed standard procedures for this test, requesting an obligatory choice 
from one of four options for each odor. 
Where one question was unanswered, the total of the 39 answered questions was scaled up 
by multiplying the total by 40/39. If <39 questions were answered, then the olfaction scores 
were not used. 
Where one question was unanswered, the total of the 39 answered questions was scaled up 
by multiplying the total by 40/39. If <39 questions were answered, then the olfaction scores 
were not used. 
The centile position for the olfaction score, corrected for age and sex, was estimated from 
normative data charts provided by the manufacturer (14), after smoothing the data curves 
using LOWESS techniques, and results at or below the 15th centile were considered as 
hyposmic. 
Patients with temporary nasal obstruction from viral or similar causes had their assessment 
deferred, and patients with sinunasal disorders were not tested. 
 
Genetic testing 
Whole-geŶoŵe DNA aŵpliﬁĐatioŶ ǁas peƌ-formed and then used for mutational screening 
by direct sequencing in Parkin, PINK1 and GBA. LRRK2 genotyping for the G2019S point 
mutatioŶ usiŶg a ͚Koŵpetitiǀe͛ allele-speĐiﬁĐ polǇmerase chain reaction (KASP) assay (LGC 
Genomic solutions) was also performed. Copy number variation in the Parkin gene was 
analyzed by multiplex ligation-depeŶdeŶt pƌoďe aŵpliﬁĐatioŶ ;MLPAͿ usiŶg speĐiﬁĐ kits 
(oďtaiŶed fƌoŵ M‘C HollaŶdͿ aĐĐoƌdiŶg to the ŵaŶufaĐtuƌeƌ͛s pƌotoĐol. 
 
Additional assessments 
While the primary objective was the examination of olfaction in relation to Parkin mutation 
status, detailed motor and cognitive assessments were also performed. Motor function was 
assessed aĐĐoƌdiŶg to paƌt ϯ of the MoǀeŵeŶt Disoƌdeƌ SoĐietǇ uŶiﬁed PD ƌatiŶg sĐale 
(MDS-UPDRS3) and Hoehn and Yahr staging (15, 16). Cognition was assessed using the 
Montreal cognitive assessment (MoCA) questionnaire (17). The non-motor symptom score 
(NMSS) was calculated using the validated 30-item NMSS scale (18). Levodopa equivalent 
daily dose was calculated by an established dose equivalence method (19). 
 
Statistical Analysis 
UŶiǀeƌsitǇ of PeŶŶsǇlǀaŶia sŵell ideŶtiﬁĐatioŶ test sĐoƌes ǁere calculated as the number of 
correct answers provided, ranging from 0 to 40. Statistical analysis was performed with the 
UPSIT scores as the primary outcome, correcting for age, gender, and smoking status 
(categorized into never, passive, ex, or current smoker) as olfactory scores are known to 
decline with increasing age, and are lower in males and smokers. 
Fisheƌ͛s eǆaĐt test foƌ ĐategoƌiĐal ǀaƌiaďles aŶd ANOVA ;ǁheƌe the residuals were normally 
disributed) or Kruskal–Wallis (where residuals were not normally distributed) tests for 
continuous variables were performed for univariate comparisons among groups for 
demographic features. For the primary outcome of UPSIT olfactory performance, 
multivariable linear regression models were used to compare UPSIT scores for the three 
patient groups (Parkin compound heterozygotes, Parkin single heterozygotes, and non-
carriers of the Parkin mutation), adjusting for age (as a continuous variable), gender, disease 
duration (as a continuous variable), and smoking behavior as deﬁŶed aďoǀe. We ĐheĐked 
the linearity assumption for age and disease duration by analysing univariate models, with 
the variables grouped into quintiles. Residuals from the UPSIT regression models were 
examined for normality. We then derived the mean differences in UPSIT scores for 
compound and single heterozygotes compared to non-carriers conditioned on being male, 
non-smoking, and of average age and dis-ease duration. 
 
Results 
Of 344 young onset PD cases, 8 (2.3%) were Par-kin compound heterozygotes and 13 (3.8%) 
were Parkin single heterozygotes. There were 9 (2.6%) LRRK2 mutation-positive cases, 44 
(12.8%) GBA cases, and 10 (2.9%) PINK1 cases. Demographics and univariate comparisons 
are described in Table 1. Olfaction, motor, and non-motor scores are shown in Table 2. 
Olfaction results were inadequate (<39 odors scored) in 62 cases, leaving 282 cases for 
aŶalǇsis. Theƌe ǁeƌe Ŷo sigŶiﬁĐaŶt age, seǆ, ĐogŶitioŶ, oƌ ŵotoƌ sĐoƌe diffeƌeŶĐes ďetǁeeŶ 
patients completing the olfaction test successfully, compared to those in whom test results 
were incomplete (data not shown). Of the 282 scores that were assessed, 276 had scored all 
40 odor scores (97.9% of cases with usable olfaction results) and six had scored 39 of 40 
odor scores (2.1% of cases with usable olfaction results). In the Parkin mutation-positive 
cases, usable olfaction results were available in 17 of 21 cases (eight of eight compound 
heterozygotes, and nine of 13 single heterozygotes). 
 
Table 1 Demographic characteristics in 344 patients with young onset PD tested for Parkin 
mutations 
 
 
 
Table 2 Olfactory, motor, non-motor, and cognitive scores in young onset PD cases tested 
for Parkin mutations 
 
 
Numbers are median (interquartile range) except where indicated.  
In Parkin compound heterozygotes, the median UPSIT score was 33, inter-quartile range 
(IQR) 28.5–ϯϲ.ϱ, ǁhiĐh ǁas sigŶiﬁĐaŶtlǇ ďetteƌ thaŶ iŶ Paƌkin single heterozygotes (median 
19, IQR 18–28) and non-carriers with a diagnosis of PD (median score 22, IQR 16–28) 
(ANOVA P < 0.001). These differences persisted after adjusting for age, disease duration, 
gender, and smoking behavior (P < 0.001). Although UPSIT generates an ordinal score, all 
residuals were normally distributed. Theƌe ǁas Ŷo sigŶiﬁĐaŶt difference in olfaction scores 
between Parkin single heterozygotes and non-carriers (P = 0.90), which persisted after 
adjustment for covariates. 
Using our multivariable model, the average UPSIT score for a Parkin mutation non-carrier 
was 19.1 for a male, non-smoker with an average age of 52.3 years, and average disease 
duration of 8.5 years. In comparison with non-carriers, the change in UPSIT score for a single 
heterozygote with the same characteristics was  0.09 (95% CI:  4.4 to 4.3; P-value = 0.97) 
and for a compound heterozygote was 11.5 (95% CI: 6.8–16.3; P-value <0.001). 
Results from statistical comparisons between groups in Tables 1 and 2 were similar after 
excluding cases which tested positive for LRRK2, GBA, or PINK1 (data not shown). 
 
Discussion 
 
The prevalence of Parkin mutations in young onset PD cases varies by ethnicity, and country 
of origin, with reported prevalence ranges ranging from 2.9% to 11.1% (20–23). The 2.3% 
prevalence rate of Parkin-related disease (compound heterozygote or homozygote 
mutations) in the present study is comparable to a previous systematic review of young 
onset PD patients from the UK (24). The 3.8% rate of Parkin single heterozygotes in our 
study is almost identical to that in a US study (3.9% of 956 young onset PD cases)(7), and to 
the background rate of 3.7% in healthy subjects (10). 
While autosomal recessive young onset parkinsonism caused by Parkin gene mutations was 
Discussion initially described in Japan as one of the mono-genic forms of PD, a wide variety 
of mutations and (less commonly) deletions in the Parkin gene can cause parkinsonism in 
people of European ancestry (25). None of our patients had homozygous Parkin mutations, 
which is again consistent with prior UK observations, while noting that other European 
studies found homozygous Par-kin mutations to be more common than heterozygous Parkin 
mutations (24, 26). 
We applied the British version of the UPSIT test, developed by Sensonics Inc (Haddon 
Heights, NJ, USA), which is largely similar in design and use to their original United States 
(US) version. However, the British version replaces a limited number of odors and 
corresponding choices (e.g. root beer) with more familiar odors for UK users. As the UK and 
US ǀeƌsioŶs of the UPSIT ƌetaiŶ sufﬁĐieŶt hoŵology in administration and interpretation of 
data, it is reasonable to compare olfaction score results across studies using these 
analogous versions. This approach appears preferable to the application of the US version to 
UK subjects, which risks misclassiﬁĐatioŶ of Ŷoƌŵal iŶdiǀiduals as ŵildlǇ hǇposŵiĐ, unless 
weighted scores are calculated after omitting the less familiar odors (27). 
Olfaction has been the subject of few prior stud-ies with detailed Parkin mutation analysis in 
patients with PD. Olfaction in Parkin-related dis-ease is reported to be normal, or near 
Ŷoƌŵal, aŶd diffeƌs sigŶiﬁĐaŶtlǇ fƌoŵ patieŶts ǁith ǇouŶg oŶset PD ǁithout Paƌkin 
mutations and from cases diagŶosed as ͚idiopathiĐ͛ PD. This aloŶg ǁith Ŷeuropathologic and 
clinical characteristics such as long disease duration has led some to hypothesize that young 
onset PD due to Parkin gene mutations is a separate disease entity (4). More recently, a 
large US study showed that olfaction in young onset PD is related to Parkin gene mutation 
status, and those with compound heterozygote mutations in this gene have preserved 
olfactory function, unlike those with single heterozygote mutations and non-carriers. Our 
results are largely similar to and validate the observations from the US study (7, 8). The 
diffeƌeŶĐes iŶ UPSIT sĐoƌes iŶ ďoth studies ƌeŵaiŶed sigŶiﬁĐaŶt eǀeŶ afteƌ adjustŵeŶt foƌ 
age, gender, disease duration, and smoking status. Our observations therefore lend support 
to the hypothesis that olfactory loss in cases of PD with Parkin single heterozygosity may be 
due to theiƌ haǀiŶg ͚idiopathiĐ͛ PD aŶd that the PaƌkiŶ siŶgle ŵutatioŶ status ŵaǇ ďe 
incidental, as opposed to the well-recognized phenomenon of preserved olfaction in Parkin-
related disease (compound heterozygotes and homozygotes). However, the possibility that 
Parkin single heterozygosity could coexist with other risk factors and lead to PD can-not be 
excluded by our olfaction results. It is also interesting to note that preserved olfaction in 
Par-kin compound heterozygotes so far appears unique among the monogenic types of PD, 
where olfactoƌǇ loss geŶeƌallǇ ŵatĐhes that of ͚idiopathiĐ͛ Đases of PD ;Ϯϴ–30), although one 
study found less marked olfactory loss in PD cases with LRRK2 mutations than those with 
sporadic PD (31). 
While ǁe oďseƌǀed gƌoup diffeƌeŶĐes iŶ UPSIT sĐoƌes that ǁeƌe statistiĐallǇ sigŶiﬁĐaŶt, 
when comparing Parkin compound heterozygotes to Parkin single heterozygous mutation 
carriers and non-carriers with PD, caution is required when interpreting the results of 
olfaction testing in the individual patient. Two of our eight Parkin com-pound 
heterozygotes, with PD durations of 18 and 29 years, were hyposmic scoring below the 15th 
centile using UPSIT normative data. Further, some of our Parkin single heterozygotes, and 
some of our non-carriers were normosmic. Accordingly, olfactory test results alone cannot 
be used to predict Parkin mutation status. 
The preserved olfaction in Parkin compound heterozygotes (and presumably homozygotes) 
Đoŵpaƌed to ͚idiopathiĐ͛ PD is oŶe component of a wider pattern of distinguishing features. 
Young age at onset, more symmetric involvement, dystonia at presentation, brisk deep 
teŶdoŶ ƌeﬂeǆes, a good ƌespoŶse to leǀodopa theƌapǇ ;ϯϮͿ, aŶd ŵoƌe sǇŵŵetƌiĐ aŶd ŵoƌe 
marked reduction of dopamine uptake on 123I FP-CIT SPECT scan (DaTSCAN) are found in 
Parkin-related disease (33, 34). Parkin mutation carriers (homozygous or compound 
heterozygous) also show better cognitive and motor performance than non-carriers, 
suggesting slower disease progression in cross-sectional studies, although longitudinal 
studies aƌe ƌeƋuiƌed to ĐoŶﬁƌŵ this ;ϯϱͿ. PaƌkiŶ ďi-allelic mutation carriers have less 
extensive distribution of Lewy bodies neuropathologically, that may not follow Braak 
staging, and spares olfactory structures (5). The sparing of olfactory structures in Parkin-
related disease may explain their pre-served olfaction. 
There are some limitations to our study such as a lack of an internal control group of healthy 
people. This meant that we had to compare the rate of Parkin single heterozygosity in our 
study cohort to that published in the literature for nor-mal healthy subjects, and while we 
have tried to answer the question about the relevance of Par-kin single mutations in young 
onset PD, this study has not answered the question of their relevance to PD in general. We 
are now undertaking a more detailed analysis of the olfactory testing in our larger cohort of 
recent onset PD cases, to examine for factors that associate with preserved olfaction, as 
well as features that correlate with moderate to severe hyposmia in the early stages 
of disease. 
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